To evaluate the impact of race (African-American [AA] vs. Caucasians [C]) on the survival and local control outcomes in cervical cancer (FIGO stage IB2-IVA) patients in a University medical center. This is a retrospective analysis of 147 cervical cancer patients diagnosed with stage IB2 to IVA who underwent concurrent chemo radiotherapy followed by brachytherapy between 2005 and 2018. Ninety-six (65.3%) AA patients and fifty-one (34.7%) C patients diagnosed with cervical cancer were treated in our academic state institution. For all the patients, local control [LC], and overall survival [OS] were estimated using Kaplan-Meier method. The racial significance of the survival variables were analyzed using the Cox regression model. A p-value of less than 0.05 was considered statistically significant. The SPSS v.24.0 was used for data analyses. The baseline characteristics of all 147 cervical cancer patients were documented; median age was 55 y (range 28-83 y) and median follow-up was 32 months (range 0 to 164 months). The C patients had 5-year OS rate of 64.2% vs. 46.6% for AA patients (p = 0.139). In the bi-variate Cox regression analysis, the covariates stratified by race, type of insurance, BMI, smoking pack years [py] were statistically significant with p-value less than 0.05. In the multivariate analysis, the covariates of insurance-private was associated with 73% reduction (hazard ratio [HR], 0.27; 95% CI, 0.11-0.66; p = 0.004), insurance-self pay with 71% reduction (HR, 0.29; 95% CI, 0.11-0.76; p = 0.012), insurance-Medicare with 43% reduction (HR, 0.56; 95% CI, 0.32-0.97; p = 0.039), BMI–normal with 76% reduction (HR, 0.24; 95%CI, 1.21-5.11; p = 0.013), py ≤ 10 years with 53% reduction (HR, 0.47; 95% CI, 0.26-0.86; p = 0.014), and ethnicity-C with 53% reduction in the risk of death (HR, 0.47; 95% CI, 0.26-0.86; p = 0.014). In terms of LC, the C patients had a 3-year rate of 50.7% vs. 42.9% for AA patients (p = 0.398). In many disease sites, AA patients have worse outcomes compared to C patients. In our cohort of patients with non-metastatic cervix cancer, we did not identify any racial differences in outcomes.